Current landscape of tropomyosin receptor tyrosine kinase inhibitors.

IF 3.2 4区医学 Q3 CHEMISTRY, MEDICINAL Future medicinal chemistry Pub Date : 2024-09-26 DOI:10.1080/17568919.2024.2403968

Hala B El-Nassan

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肌球蛋白受体酪氨酸激酶抑制剂的现状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future medicinal chemistry CHEMISTRY, MEDICINAL-

CiteScore

5.80

自引率

2.40%

发文量

118

审稿时长

4-8 weeks

期刊介绍： Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.

期刊最新文献

Current landscape of tropomyosin receptor tyrosine kinase inhibitors. Benzimidazole-based small molecules as anticancer agents targeting telomeric G-quadruplex and inhibiting telomerase enzyme. Novel benzimidazole-based azine derivatives as potent urease inhibitors: synthesis, in vitro and in silico approach. Organotellurium (IV) complexes as anti-malarial agents: synthesis, characterization and computational insights. Exploring biological activities of novel Schiff bases derived from amlodipine and in silico molecular modeling studies.